Our company provides many development opportunities such as workshops, specific trainings and ability to participate in international conferences. For sport enthusiast we offer co-funding of the Multisport card. We offer fresh fruits in break room for our workers to enjoy throughhout the day. Team outings and fun events are being frequently organised. Captor Therapeutics is a drug discovery and development company applying targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases with significant. We make sure that our staff feel welcome, respected and appreciated. We encourage our employees to work, brainstorm and problem solve together. Our employees can choose their working hours, starting anytime from 7 AM to 10 AM. Every employee is firstly offered a three-month trial period, followed by an employment contract for an indefinite duration with a competitive salary.Ĭaptor Therapeutics currently consists of more than 35 employees, creating young and enthusiastic team of scientist both at PhD and Masters level with experties in molecular biology and early stages of drug development, supported by experienced professionals. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed undruggable. DegScreen will also comprise the use of an innovative optimized biased chemical compounds library with special purpose (developed by Captor Therapeutics), whose parameters are selected to bias the library towards higher potential of induced protein degradation in cells.Flexible work schedules and employment conditions Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. Szeroko rozumiana brana biotechnologiczna jest obecnie jednym z najgortszych tematów inwestycyjnych na GPW. The technology will be implemented in the market as a service which enables screening for compounds active towards a chosen protein to be used as potential drug precursors, auxiliary compounds for determination of protein function or their role in pathogenic processes, and for assessment of the drug candidates polipharmacological profile. Captor Therapeutics z IPO chce pozyska do 150 mln z na rozwój i badania nowych leków. The applicants challenge this issue by proposing an innovative DegScreen technology – a two-step high-throughput screening of low molecular weight compounds which induce the degradation of protein target. A crucial problem which limits the induced protein degradation technology development based on degrons is a lack of quick, efficient and high-throughput assays enabling the detection of compounds which exhibit preferred activity. Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune. cancer-involved proteins, amyloids) or exogenic proteins (e.g. Degrons can be used towards both endogenic (e.g. The most substantial fact is that their efficiency is not dependent on the enzymatic or binding function of the target protein, which enables identification of new therapeutic targets, approaching which was not possible until recently (“undruggable proteome”, estimated to cover even 80% of human proteome). The application of drugs based on degron-like compounds brings major advantage over classic therapies. Sosei Heptares spin-off Company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals READ MORE. One of new fields within this scope is degradation of specific proteins in the cell induced by low molecular weight compounds (called degrons), whose therapeutic potential cannot be overestimated. Get the latest Captor Therapeutics Spolka Akcyjna Bearer Shs Reg S stock price and detailed information including news, historical charts and realtime. The drug discovery market is characterized by high investment rate and constant development towards innovative technologies and mechanisms. SUB-MEASURE 4.1.4: „Application projects” PRIORITY AXIS IV: INCREASING THE RESEARCH POTENTIAL Project supported by the National Centre for Research and Development under the Smart Growth Operational Programme 2014-2020 TPD is a revolutionary approach to developing new drugs that can target new molecular targets considered. „Development and implementation of an innovative platform for screening analysis of therapeutic degron-type compounds” 'Captor Therapeutics' Spolka Akcyjna operates as a biopharmaceutical company. About Captor Therapeutics Captor Therapeutics is a drug discovery and development company applying targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases with significant unmet medical need. Ścieżka powrotu PORT > O nas > Projekty > DegScreen DegScreen
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |